PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma

BACKGROUND: After liver resection (LR), patients with hepatocellular cancer (HCC) are at high risk of recurrence. There are no approved anti-cancer therapies known to affect such risk, highlighting the acute need for novel systemic therapies to control the probability of disease relapse. Immunothera...

Descripción completa

Detalles Bibliográficos
Autores principales: Pinato, David J., Cortellini, Alessio, Sukumaran, Ajithkumar, Cole, Tom, Pai, Madhava, Habib, Nagy, Spalding, Duncan, Sodergren, Mikael H., Martinez, Maria, Dhillon, Tony, Tait, Paul, Thomas, Robert, Ward, Caroline, Kocher, Hemant, Yip, Vincent, Slater, Sarah, Sharma, Rohini
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7988931/
https://www.ncbi.nlm.nih.gov/pubmed/33757459
http://dx.doi.org/10.1186/s12885-021-08033-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7988931/
https://www.ncbi.nlm.nih.gov/pubmed/33757459
http://dx.doi.org/10.1186/s12885-021-08033-x

Ejemplares similares